Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome

• Status: Recruiting
• Trial end date: 2022-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators are testing treatment with low-dose naltrexone (LDN) for symptom relief of complex regional pain syndrome (CRPS). Study participants will be randomly assigned to receive either LDN or placebo for a period of several weeks. During this period participants will be asked to come to several visits, which will include sensory testing, physical assessments, and questionnaires.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Stanford University
• Treatments: Naltrexone

Criteria

Inclusion Criteria:

• Upper and/or lower extremity CRPS

• On stable treatment for 3 months

• CRPS for at least 1 year

• Meet the Budapest criteria for CRPS at time of the study.

Exclusion Criteria:

• Any known allergy to naltrexone or naloxone

• Use of prescription opioid analgesics or illegal opioid use

• Current of planned pregnancy.